{"capabilities":{"streaming":false},"defaultInputModes":["text/plain"],"defaultOutputModes":["text/plain"],"description":"R&D instance for experimental protocols, assay development, process optimization, and compound registry. Houses preclinical data, formulation history, and biomarker validation.","name":"R&D L7|ESP","preferredTransport":"JSONRPC","protocolVersion":"0.3.0","security":[{"BearerAuth":[]}],"securitySchemes":{"BearerAuth":{"description":"L7|ESP API Bearer token. Validated via GET /api/profile on the local L7|ESP instance.","scheme":"bearer","type":"http"}},"skills":[{"description":"R&D instance for experimental protocols, assay development, process optimization, and compound registry. Houses preclinical data, formulation history, and biomarker validation.","examples":["What experiments have been run on compound LY-123456 this year?","What changed in process version PD-v4.3 compared to PD-v4.2?","What is the validation status of biomarker BM-0047 (FOXO1 nuclear exclusion)?"],"id":"ask_l7esp","name":"Ask R&D","tags":["esp","askl7","l7esp","r-d"]}],"url":"https://ask-rnd.l7esp.com/","version":"1.0.0"}